GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 NOTES TO THE FINANCIAL STATEMENTS for the year ended March 31, 2022 190 Note 17 : share capital ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Authorised 1,500,000 (Previous year : 1,500,000) Equity Shares of ` 10 each 1,50.00 1,50.00 ISSUED, SUBSCRIBED & PAID-UP: 960,000 (Previous year : 960,000) Equity Shares of ` 10 each fully paid up 96.00 96.00 (of the above 750,000 ordinary shares have been allotted as fully paid-up Bonus shares by capitalisation of General Reserve) TOTAL 96.00 96.00 a) Shares held by holding company Equity Shares of ` 10 each 960,000 (Previous year : 960,000) held by GlaxoSmithKline Pharmaceuticals Limited, the Holding Company 96.00 96.00 As at March 31, 2022 As at March 31, 2021 Number of Shares ` in lakhs Number of Shares ` in lakhs b) Reconciliation of the number of shares Balance at the beginning of the year 960,000 96.00 960,000 96.00 Issued during the year - - - - Balance at the end of the year 960,000 96.00 960,000 96.00 c) Rights, preferences and restrictions attached to equity shares: The company has only one class of equity shares having a par value of Rs 10/- per share. Each share holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders. d) Details of shareholders holding more than 5% shares in the company: ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Number of Shares Number of Shares GlaxoSmithKline Pharmaceuticals Limited, the Holding Company 960000 {100%} 960000 {100%} Note 18 : Revenue from operations ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 A. Sale of products (gross) Sale of products 80,66.00 12,56.22 80,66.00 12,56.22 B. Other operating revenue Others 16.46 - 16.46 - Total Revenue from operations 80,82.46 12,56.22 Note 19 : Other income ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Interest income 0.11 38.71 Provisions written back (net) 0.67 - Miscellaneous Income 0.01 0.78 0.79 39.49 Note 20 : Cost of materials consumed ( ` in lakhs) Year ended March 31, 2022 Year ended March 31, 2021 Cost of materials consumed 58,70.57 19,38.60